Onasemnogene abeparvovec for the treatment of spinal muscular atrophy

Taylor and Francis Group, Expert Opinion on Biological Therapy, 9(22), p. 1075-1090, 2022

Journal article published in 2022 by Hugh J. McMillan

Distributing this paper is prohibited by the publisher

Full text: Unavailable

Preprint: archiving forbidden

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by